Updated Cochrane review finds PSA screening reduces prostate cancer mortality
A new systematic review published in 2026 concludes that prostate-specific antigen blood testing likely reduces the risk of death from prostate cancer, though over-diagnosis and over-treatment remain concerns.
A new systematic review, covered by STAT News on 15 May 2026, finds that PSA (prostate-specific antigen) screening for prostate cancer likely reduces prostate-cancer-specific mortality. The review is described as a Cochrane-style meta-analysis synthesising evidence from randomised trials.
The findings are consistent with the direction of recent European trial data, including long-term follow-up from the ERSPC (European Randomised Study of Screening for Prostate Cancer), while the persistent tension between benefit and the harms of over-diagnosis — detection of cancers that would not have caused symptoms or death — remains a central caveat. The balance between those harms and the mortality reduction is the key variable informing published guidelines from bodies including NICE and the USPSTF.
This is an area of active research relevance to GPs navigating patient conversations about prostate cancer risk, to oncologists, and to genetic counsellors supporting men with hereditary cancer syndromes (such as pathogenic variants in BRCA2, ATM, or HOXB13) who may be at elevated risk. Published guidance from relevant bodies should be consulted for any decisions about screening in clinical settings. The review does not alter published guidelines on its own but adds to the evidence base informing them.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Prostate-specific antigen (PSA) is a protein made by the prostate gland, and a blood test can measure its level. A new review of research studies, published in 2026, finds that having this test carried out regularly probably reduces the chance of dying from prostate cancer. However, researchers note that PSA testing can also lead to finding cancers that might never have caused any harm — which can result in treatments that have side effects but were not necessary. This balance between benefit and potential over-treatment is why expert bodies have different recommendations on PSA screening. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-05-15PSA screening for prostate cancer reduces disease-specific deaths, new review shows